Markets:

Overview

News

Currencies

International

Treasuries

Pacific Biosciences of California, Inc. - Common Stock (NQ:PACB)

1.400 -0.080 (-5.41%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacific Biosciences of California, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Mid-Afternoon Market Update: Dow Rises 150 Points; Accolade Shares Spike Higher ↗

January 11, 2022

Toward the end of trading Tuesday, the Dow traded up 0.43% to 36,224.50 while the NASDAQ rose 1.33% to 15,142.08. The S&P also rose, gaining, 0.75% to 4,705.23. The U.S. has...

Via Benzinga

Illumina Jumps As Gene Sequencing Demand Drives Stronger Outlook ↗

January 11, 2022

Piper says Pacific Bio has a new competitor in Illumina amid plans to launch what looks like a consumable allowing long-read sequencing on its analyzers.

Via Talk Markets

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 11, 2022

Gainers Nutriband (NASDAQ:NTRB) stock moved upwards by 20.7% to $7.29 during Tuesday's regular session. Trading volume for Nutriband's stock is 6.4 million as of...

Via Benzinga

Mid-Day Market Update: Crude Oil Rises 3.5%; Pacific Biosciences of California Shares Fall ↗

January 11, 2022

Midway through trading Tuesday, the Dow traded down 0.50% to 35,889.26 while the NASDAQ fell 0.16% to 14,919.61. The S&P also fell, dropping, 0.39% to 4,652.01. The U.S. has...

Via Benzinga

Earnings Scheduled For November 2, 2021 ↗

November 02, 2021

Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion. •...

Via Benzinga

30 Stocks Moving In Tuesday's Mid-Day Session ↗

January 11, 2022

Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year....

Via Benzinga

52 Weeks High And Low Article ↗

January 11, 2022

Stocks that Broke Yearly Lows Tuesday Morning During Tuesday's morning trading, 87 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Highs And Lows: 10x...

Via Benzinga

The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In ↗

January 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

January 11, 2022

Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock increased by 18.2% to $5.32 during Tuesday's pre-market session. The market value of their outstanding shares is...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

January 11, 2022

Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

21 Stocks Moving in Tuesday's Pre-Market Session ↗

January 11, 2022

Gainers OneSmart International Education Group Limited (NYSE: ONE) rose 39.1% to $0.2701 in pre-market trading. OneSmart International Education Group received notification from...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

January 10, 2022

Gainers Inari Medical (NASDAQ:NARI) stock...

Via Benzinga

Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗

December 22, 2021

The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022.

Via Talk Markets

Looking for Growth in Small and Mid Cap Life Science Stocks ↗

November 15, 2021

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

Via Talk Markets

Earlier Screening and Aging Population Driving Surging Growth in Colorectal Diagnostics Demand

November 11, 2021

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – November 11, 2021 – New recommendations for colorectal cancer (CRC) screening by both the US Preventative Services Task Force...

Via FinancialNewsMedia

Pacific Biosciences Q3 Revenues Jump 83%, Says Sequel II/IIe Installations At All-Time High ↗

November 03, 2021

Pacific Biosciences of California Inc (NASDAQ: PACB) reported Q3 sales of $34.9 million, beating the consensus of $33.23 million and up 83% Y/Y. The company...

Via Benzinga

Pacific Biosciences of California (PACB) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

PACB earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗

November 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

3 Genomics Stocks That Could Soar 60% or Better, According to Wall Street ↗

October 27, 2021

The genomic revolution is upon us and these stocks could be great vehicles for investors who want to take advantage of it.

Via The Motley Fool

Class Of 2010: A Decade After Their IPOs, Where Are These Companies Now? ↗

October 10, 2021

The year 2010 was a bumper year for IPOs, as more than twice as many new issues were floated as compared to the previous year. The IPO boom of the year was spearheaded by special purpose acquisition...

Via Talk Markets

Topics Initial Public Offering

Class Of 2010: A Decade After Their IPOs, Where Are These Companies Now? ↗

October 10, 2021

Initial public offerings provide companies with the wherewithal to pursue growth opportunities without having to bear the burden of repayment. What Is an IPO: An IPO is a...

Via Benzinga

Topics Initial Public Offering

5 Largest US M&A Deals In Q2: Railways, Health Care, REITS And More ↗

September 06, 2021

The second quarter started strong with four of the five largest deals announced in the month of April.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021 ↗

September 27, 2021

Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ:

Via Benzinga

5 Largest US M&A Deals In Q2: Railways, Health Care, REITS And More ↗

September 06, 2021

Global merger and acquisition activity topped $1 trillion in the second quarter of 2021, with the U.S alone topping $500 billion. This was the third quarter in a row that this...

Via Benzinga

Week In Review: China Life Science Posts $1.3 Billion In Deals ↗

August 07, 2021

Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome for up to $800 million. Zai Lab and Schrödinger formed a collaboration to develop a...

Via Talk Markets

Billionaire Masayoshi Son's SoftBank Claims $5B Stake In Roche: Bloomberg ↗

August 04, 2021

SoftBank Group Corp (OTC: SFTBF) has quietly acquired a $5 billion stake in Roche Holdings AG (OTC: RHHBF), making it one of the largest investors of the Roche,...

Via Benzinga

Pacific Biosciences of California (PACB) Q2 2021 Earnings Call Transcript ↗

August 04, 2021

PACB earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Pacific Biosciences Q2 Earnings Beat Expectations, Higher Operating Costs Widens Quarterly Loss ↗

August 04, 2021

Pacific Biosciences of California Inc (NASDAQ: PACB), after the close of the market on Tuesday, reported Q2 sales of $30.6 million, beating the consensus of $29.9...

Via Benzinga

Topics Earnings

$5,000 Invested in These 3 Healthcare Stocks Could Make You Rich Over the Next 10 Years ↗

August 04, 2021

These companies could upend the industry in the years ahead.

Via The Motley Fool

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.